Clinical Trial Detail

NCT ID NCT02503358
Title Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors OHSU Knight Cancer Institute
Indications

non-small cell lung carcinoma

Therapies

Selumetinib

nab-paclitaxel

Age Groups: adult

Additional content available in CKB BOOST